Muscarinic acetylcholine receptors as CNS drug targets

被引：329

作者：

Langmead, Christopher J. ^{[1
]}

Watson, Jeannette ^{[1
]}

Reavill, Charlie ^{[1
]}

机构：

[1] GlaxoSmithKline, Psychiat Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England

来源：

PHARMACOLOGY & THERAPEUTICS | 2008年 / 117卷 / 02期

关键词：

muscarinic receptors; mAChR; CNS; Alzheimer's disease; schizophrenia; Parkinson's disease; drug dependence;

D O I：

10.1016/j.pharmthera.2007.09.009

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Muscarinic acetylcholine receptors (mAChRs) are widely expressed in the CNS where they control a variety of neuronal functions. Due to their roles in a number of CNS processes, mAChRs have long been a target of the drug discovery industry; however, the only mAChR ligands approved for use in the clinic are non-selective antagonists for the treatment of Parkinson's disease. This article briefly reviews recent progress made in mAChR drug discovery for Alzheimer's disease (AD), schizophrenia and Parkinson's disease, with particular emphasis on novel target validation, as well as highlighting novel indications such as drug addiction. (c) 2007 Elsevier Inc. All rights reserved.

引用

页码：232 / 243

页数：12

共 118 条

[1] Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice [J].

Anagnostaras, SG ;

Murphy, GG ;

Hamilton, SE ;

Mitchell, SL ;

Rahnama, NP ;

Nathanson, NM ;

Silva, AJ .

NATURE NEUROSCIENCE, 2003, 6 (01) :51-58

[2]

[Anonymous], 2002, Mov Disord, V17 Suppl 4, pS7

[3] Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia [J].

Basile, AS ;

Fedorova, I ;

Zapata, A ;

Liu, XG ;

Shippenberg, T ;

Duttaroy, A ;

Yamada, M ;

Wess, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (17) :11452-11457

[4] Cholinergic fibre loss associated with diffuse plaques in the non-demented elderly: The preclinical stage of Alzheimer's disease? [J].

Beach, TG ;

Honer, WG ;

Hughes, LH .

ACTA NEUROPATHOLOGICA, 1997, 93 (02) :146-153

[5]

BILLARD W, 1995, J PHARMACOL EXP THER, V273, P273

[6] Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice [J].

Billings, LM ;

Oddo, S ;

Green, KN ;

McGaugh, JL ;

LaFerla, FM .

NEURON, 2005, 45 (05) :675-688

[7]

BLAHA CD, 1993, J NEUROSCI, V13, P1035

[8] Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease [J].

Bodick, NC ;

Offen, WW ;

Levey, AI ;

Cutler, NR ;

Gauthier, SG ;

Satlin, A ;

Shannon, HE ;

Tollefson, GD ;

Rasmussen, K ;

Bymaster, FP ;

Hurley, DJ ;

Potter, WZ ;

Paul, SM .

ARCHIVES OF NEUROLOGY, 1997, 54 (04) :465-473

[9] Synthesis and pharmacology of benzoxazines as highly selective antagonists at M4 muscarinic receptors [J].

Böhme, TM ;

Augelli-Szafran, CE ;

Hallak, H ;

Pugsley, T ;

Serpa, K ;

Schwarz, RD .

JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (14) :3094-3102

[10] Developing drugs for cognitive impairment in schizophrenia [J].

Breier, A .

SCHIZOPHRENIA BULLETIN, 2005, 31 (04) :816-822

← 1 2 3 4 5 6 7 8 9 10 →